AtriCure (ATRC) 43rd Annual J.P. Morgan Healthcare Conference 2025 summary

Market opportunity and business positioning

• Targeting over $10 billion in market opportunities across atrial fibrillation, hybrid therapy, and pain management, with significant underpenetration remaining.

• Holds number one position in all served markets, supported by strong clinical evidence and innovation.

• Three main business areas: cardiac surgery (ablation and appendage management), hybrid AFib therapy, and pain management, each with substantial growth potential.

• Expansion into new indications and geographies, including extremity pain management and international markets.

• Market expansion driven by new product launches, changes in clinical guidelines, and improved reimbursement.

Financial performance and outlook

• Achieved 17% overall growth in 2024, with international growth at 26% and strong performance in cryo pain management and AtriClip franchises.

• Projecting $517–$527 million in sales for 2025, representing 11–13% growth, and $40–$44 million in adjusted EBITDA, marking the first year of cash flow positivity.

• 2024 preliminary results show $465.3M in revenue and $26M–$29M in adjusted EBITDA, with a 42% increase in positive adjusted EBITDA.

• EBITDA growth driven primarily by SG&A leverage, with continued investment in R&D and innovation.

• Gross margins expected to remain stable around 75%, balancing higher-margin new products with lower-margin international growth.

Product innovation and clinical evidence

• Five new products launched in the past year, with two more expected in 2025, accelerating adoption and market expansion.

• Innovations like Encompass clamp, AtriClip FLEX Mini, and cryoSPHERE+ have reduced procedure times and improved ease of use.

• Largest clinical trial in cardiac surgery (LEAPS) underway, with two-thirds enrollment completed, supporting expanded indications.

• Clinical evidence has led to upgrades in treatment guidelines and increased reimbursement from CMS, further opening markets.

• Key clinical trials and product development efforts include LeAAPS, BoxX-NOAF, and a PFA platform.